The $2.6 Billion Pill — Methodologic and Policy Considerations
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Interview with Dr. Jerry Avorn on a new estimate of the cost of bringing a drug to market. (12:09)Download An industry-supported center claims that it costs companies $2.6 billion to develop a new drug. But we need a broader-based and more transparent reckoning of research-and-development costs to inform discussions about fostering innovation and paying for medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kesselheim, A. S., Tan, Y. T., & Avorn, J. (2015) · Health Affairs · doi:10.1377/hlthaff.2014.1038 · Cited by 143
Self-citationDiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1504317 · Cited by 118
Cited by
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020) · Cell Discovery · doi:10.1038/s41421-020-0153-3 · Cited by 1,597
Induced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531
Regenerative medicine: Current therapies and future directions
Mao, A. S., & Mooney, D. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508520112 · Cited by 941
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Artificial intelligence in COVID-19 drug repurposing
Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30192-8 · Cited by 636
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform
Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016) · JAMA · doi:10.1001/jama.2016.11237 · Cited by 592
Self-citationdeepDR: a network-based deep learning approach to in silico drug repositioning
Zeng, X., Zhu, S., Liu, X., Zhou, Y., Nussinov, R., & Cheng, F. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz418 · Cited by 535
Prasad, V., & Mailankody, S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3601 · Cited by 503
IBM Watson: How Cognitive Computing Can Be Applied to Big Data Challenges in Life Sciences Research
Chen, Y., Elenee Argentinis, J., & Weber, G. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.12.001 · Cited by 466
The high price of anticancer drugs: origins, implications, barriers, solutions
Prasad, V., De Jesús, K., & Mailankody, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.31 · Cited by 442
Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
How much does it cost to research and develop a new drug? A systematic review and assessment
Schlander, M., Hernandez-Villafuerte, K., Cheng, C.-Y., Mestre-Ferrandiz, J., & Baumann, M. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01065-y · Cited by 360
“Third, some critics argue that the opportunity costs should not be considered and that the discount rates (cost of capital [COC]) applied were too high [20, 24, 26, 27, 31].”
BackgroundMethodInfluentialTarget identification among known drugs by deep learning from heterogeneous networks
Zeng, X., Zhu, S., Lu, W., Liu, Z., Huang, J., Zhou, Y., Fang, J., Huang, Y., Guo, H., Li, L., et al. (2020) · Chemical Science · doi:10.1039/c9sc04336e · Cited by 357
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Nanophotonic Approaches for Chirality Sensing
Warning, L. A., Miandashti, A. R., McCarthy, L. A., Zhang, Q., Landes, C. F., & Link, S. (2021) · ACS Nano · doi:10.1021/acsnano.1c04992 · Cited by 342
Zeng, X., Xiang, H., Yu, L., Wang, J., Li, K., Nussinov, R., & Cheng, F. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00557-6 · Cited by 308
Deep generative molecular design reshapes drug discovery
Zeng, X., Wang, F., Luo, Y., Kang, S.-G., Tang, J., Lightstone, F. C., Fang, E. F., Cornell, W., Nussinov, R., & Cheng, F. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100794 · Cited by 295
Hagar, M., Ahmed, H. A., Aljohani, G., & Alhaddad, O. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113922 · Cited by 294
Sai, S., Gaur, A., Sai, R., Chamola, V., Guizani, M., & Rodrigues, J. J. P. C. (2024) · IEEE Access · doi:10.1109/access.2024.3367715 · Cited by 268
“Furthermore, traditional molecule development methods are costly; 2005 pharmaceutical companies spent $2.6 billion to develop new US Food and Drug Administration-approved drugs [68].”
BackgroundInfluentialRepurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning
Zeng, X., Song, X., Ma, T., Pan, X., Zhou, Y., Hou, Y., Zhang, Z., Li, K., Karypis, G., & Cheng, F. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00316 · Cited by 257
Cell Therapy: Types, Regulation, and Clinical Benefits
El-Kadiry, A. E.-H., Rafei, M., & Shammaa, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.756029 · Cited by 256
“Clinical development is also an arduous process that hinders the introduction of new products into the market (235, 236).”
BackgroundMoFlow: An Invertible Flow Model for Generating Molecular Graphs
Zang, C., & Wang, F. (2020) · Proceedings of the 26th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining · doi:10.1145/3394486.3403104 · Cited by 227
“6 billion) process with a high failure rate [1, 25].”
BackgroundThree‐dimensional cell culture models for anticancer drug screening: Worth the effort?
Verjans, E., Doijen, J., Luyten, W., Landuyt, B., & Schoofs, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26052 · Cited by 212
Vogler, S., Paris, V., Ferrario, A., Wirtz, V. J., de Joncheere, K., Schneider, P., Pedersen, H. B., Dedet, G., & Babar, Z.-U.-D. (2017) · Applied Health Economics and Health Policy · doi:10.1007/s40258-016-0300-z · Cited by 202
“Furthermore, long-lasting discussions about knowledge of production costs, including R&D costs [69, 140], have also reached Europe.”
Schomberg, D. T., Tellez, A., Meudt, J. J., Brady, D. A., Dillon, K. N., Arowolo, F. K., Wicks, J., Rousselle, S. D., & Shanmuganayagam, D. (2016) · Toxicologic Pathology · doi:10.1177/0192623315618292 · Cited by 97
“6 billion (Morgan et al. 2011; Avorn 2015) for drug and between US$75 and US$94 million for medical device (Makower, Meer, and Denend 2010) development.”
Background
Metadata
- Authors
- Avorn, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1877-1879
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W324102958
- Cited by
- 318
- References
- 2
- FWCI
- 96.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.